CSIMarket
 


Novavax inc  (NVAX)
Other Ticker:  
 
 

NVAX's Capital Expenditures Growth by Quarter and Year

Novavax Inc's Capital Expenditures results by quarter and year




NVAX Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 9.08 22.06 16.36 8.73
III Quarter September 18.39 29.52 12.19 3.76
II Quarter June 7.78 24.58 15.15 0.12
I Quarter March 23.56 16.83 13.78 0.22
FY   58.81 92.99 57.48 12.83



NVAX Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Novavax Inc reported drop in Capital Expenditures in the fourth quarter 2023 by -58.85% to $ 9.08 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Novavax Inc's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 196.79%.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Capital Expenditures growth. While Novavax Inc' s Capital Expenditures meltdown of -58.85% ranks overall at the positon no. 722 in the fourth quarter 2023.




NVAX Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -58.85 % 34.84 % 87.4 % 2325 %
III Quarter September -37.7 % 142.17 % 224.2 % 683.33 %
II Quarter June -68.35 % 62.24 % 12525 % -85.19 %
I Quarter March 39.99 % 22.13 % 6163.64 % -57.69 %
FY   -36.76 % 61.78 % 348.01 % 491.24 %

Financial Statements
Novavax Inc's fourth quarter 2023 Capital Expenditures $ 9.08 millions NVAX's Income Statement
Novavax Inc's fourth quarter 2022 Capital Expenditures $ 22.06 millions Quarterly NVAX's Income Statement
New: More NVAX's historic Capital Expenditures Growth >>


NVAX Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -50.64 % -25.27 % 34.21 % 132.18 %
III Quarter September 136.38 % 20.1 % -19.54 % 3033.33 %
II Quarter June -66.98 % 46.05 % 9.94 % -45.45 %
I Quarter March 6.8 % 2.87 % 57.85 % -38.89 %
FY (Year on Year)   -36.76 % 61.78 % 348.01 % 491.24 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #81
Overall #722

Capital Expenditures Y/Y Growth Statistics
High Average Low
3428.11 % 196.79 % -77.75 %
(Jun 30 2021)   (Sep 30 2018)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #81
Overall #722
Capital Expenditures Y/Y Growth Statistics
High Average Low
3428.11 % 196.79 % -77.75 %
(Jun 30 2021)   (Sep 30 2018)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Novavax Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
2983.61 % 81.5 % -100 %
(Jun 30 2020)  


NVAX's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Novavax Inc realized fall in Capital Expenditures from the third quarter by -50.64% to $ 9.08 millions, from $ 18.39 millions released in the previous reporting period.

But that's not big problem, as IV. Quarter Capital Expenditures frequently tend to slow in the IV. Quarter.

Within Biotechnology & Pharmaceuticals industry 26 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Novavax Inc's Capital Expenditures growth quarter on quarter, overall rank is 1660.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #27
Healthcare Sector #216
Overall #1660
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #27
Healthcare Sector #216
Overall #1660
Capital Expenditures Q/Q Growth Statistics
High Average Low
2983.61 % 81.5 % -100 %
(Jun 30 2020)  


NVAX's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Novavax Inc reported fall in Capital Expenditures from the third quarter by -50.64% to $ 9.08 millions, from $ 18.39 millions released a quarter before.

It's not big issue, as Novavax Inc's Capital Expenditures frequently gravitate to plunge in the IV. Quarter Isabelle Scott, Biotechnology & Pharmaceuticals industry expert noted.

Within Biotechnology & Pharmaceuticals industry 26 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Novavax Inc's Capital Expenditures growth quarter on quarter, overall rank is 1660.


Novavax Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 58.81 $ 71.79 $ 82.92 $ 99.72 $ 92.99
Y / Y Capital Expenditures Growth (TTM) -36.76 % -17.75 % 18.53 % 64.74 % 61.75 %
Year on Year Capital Expenditures Growth Overall Ranking # 188 # 257 # 383 # 170 # 62
Seqeuential Capital Expenditures Change (TTM) -18.09 % -13.42 % -16.84 % 7.24 % 6.53 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 722 # 659 # 944 # 1085 # 969




Cumulative Capital Expenditures growth Comment
Novavax Inc's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -36.76% year on year, at Dec 31 2023 compare to the -17.75% decrease at Sep 30 2023. If the Novavax Inc's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $59 millions.

Within the Healthcare sector 25 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 188, from total ranking in previous quarter at 257.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
3428.11 %
196.79 %
-77.75 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 26
Overall # 188

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3428.11 %
196.79 %
-77.75 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 81
S&P 500 # 722
Cumulative Capital Expenditures growth Comment
Novavax Inc's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -36.76% year on year, at Dec 31 2023 compare to the -17.75% decrease at Sep 30 2023. If the Novavax Inc's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $59 millions.

Within the Healthcare sector 25 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 188, from total ranking in previous quarter at 257.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
3428.11 %
196.79 %
-77.75 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 26
Overall # 188

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3428.11 %
196.79 %
-77.75 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 81
S&P 500 # 722




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
NVAX's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for NVAX's Competitors
Capital Expenditures Growth for Novavax Inc's Suppliers
Capital Expenditures Growth for NVAX's Customers

You may also want to know
NVAX's Annual Growth Rates NVAX's Profitability Ratios NVAX's Asset Turnover Ratio NVAX's Dividend Growth
NVAX's Roe NVAX's Valuation Ratios NVAX's Financial Strength Ratios NVAX's Dividend Payout Ratio
NVAX's Roa NVAX's Inventory Turnover Ratio NVAX's Growth Rates NVAX's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions
Natera inc -19.40%$ -19.405 millions
Capricor Therapeutics inc -19.51%$ -19.515 millions
Ardelyx Inc -21.82%$ -21.818 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com